Vidofludimus

Publications & Posters

16-18 February, 2012 7th ECCO IBD Conference, Barcelona, Spain		Vidofludimus inhibits IL-17 and improves hapten-induced colitis in young rats by a unique dual mode of action Vidofludimus induces p53-mediated apoptosis in activated T-cells and inhibits IL-17A and IL-17F expression decoupled from lymphocyte proliferation
6-7 November, 2011 Annual Scientific Meeting of the American College of Rheumatology (ACR) in Chicago, USA		Efficacy, Safety and Pharmacokinetics of Vidofludimus, a Novel Oral Immunomodulator, in Patients with Active Rheumatoid Arthritis on Methotrexate Background Therapy: The COMPONENT Study
25-28 May, 2011 EULAR London, England		Vidofludimus shows a superior profile compared to cyclophosphamide and MMF in an experimental systemic Lupus Erythematosus model
7-10 May, 2011 Digestive Disease Week, Chicago, USA		Efficacy, Safety and Tolerability of Vidofludimus in Patients with Inflammatory Bowel Disease: the ENTRANCE Study Inhibition of IL-17 Release by the Novel Anti-Inflammatory Drug Vidofludimus Involves Attenuation of STAT-3 and NF-kappa B Signaling Pathways in Murine Splenocytes and Hapten-Induced Colitis
24-26 February, 2011 6th ECCO IBD Conference, Dublin, Ireland		Efficacy, Safety and Tolerability of Vidofludimus in Patients with Inflammatory Bowel Disease: the ENTRANCE Study
18-21 February, 2011 14th International Symposium on Purine and Pyrimidine Metabolism in Man, Tokyo, Japan		Vidofludimus, a New IL-17 and DHODH Inhibitor for Treatment of Inflammatory and Autoimmune Diseases
22 April, 2010 American Journal of Pathology 2010; 176(6):2840-7		4SC-101, A Novel Small Molecule Dihydroorotate Dehydrogenase Inhibitor, Suppresses Systemic Lupus Erythematosus in MRL-(Fas)lpr Mice
22 March, 2010 Inflammatory Bowel Diseases 2010; 16(10):1763-77		4SC-101, A Novel Immunosuppressive Drug, Inhibits IL-17 and Attenuates Colitis in two Murine Models of Inflammatory Bowel Disease
28 May, 2009 Digestive Disease Week 2009, Chicago, USA		A Novel Immunosuppressive Drug (4SC–101) Improves TNBS-Induced Colitis in Mice
26 January, 2006 J. Med. Chem. 2006, 49, 1239-1247		Dual Binding Mode of a Novel Series of DHODH Inhibitors
21 October, 2005 Bioorganic & Medicinal Chemistry Letters 16 (2006) 267-270		Biphenyl-4-ylcarbamoyl thiophene carboxylic acids as potent DHODH inhibitors
6 September, 2005 Bioorganic & Medicinal Chemistry Letters 15 (2005) 4854-4857		SAR, species, specificity, and cellular activity of cyclopentene dicarboxylic acid amides as DHODH inhibitors
13 October, 2003 Bioorganic & Medicinal Chemistry Letters 14 (2004) 55–58		Discovery of a novel series of DHODH inhibitors by a docking procedure and QSAR reﬁnement